@millitzafeliciano's semaglutide experience, fact-checked

What did @millitzafeliciano actually say?

Straightforwardly: nothing about semaglutide. The transcript is song lyrics, not health advice. The words captured here, "I'm a freak bitch, I love the beast, she better eat," have no medical content whatsoever. The hashtags point to GLP-1 weight loss content, but the video itself delivers none of that. This is either a lip-sync, a background audio clip, or a mismatched caption strategy built to ride trending hashtags.

This matters because 59,200 people watched it under the semaglutide hashtag. Some portion of those viewers are people actively researching GLP-1 medications for weight loss or type 2 diabetes management. What they got instead was ambient music and zero clinical information, which is actually better than misinformation, but still worth noting as a pattern in how health hashtags get gamed for reach.

Does the science back this up?

There is no claim here to evaluate against the science. The transcript contains no assertions about semaglutide, weight loss mechanisms, dosing, side effects, or outcomes. So the honest answer is: the science is simply not in the room.

What we can say is that GLP-1 receptor agonists like semaglutide do have a robust evidence base. The STEP trials, published in the New England Journal of Medicine between 2021 and 2022 (Wilding et al., 2021, NEJM; Wadden et al., 2021, NEJM), showed sustained body weight reductions of roughly 15 percent in adults with obesity using semaglutide 2.4 mg weekly. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data. None of that evidence is referenced or misrepresented here, because the creator simply did not discuss it.

What did they get wrong (or right)?

Nothing was gotten wrong in a clinical sense because no clinical claims were made. That sounds like faint praise, but in a space where GLP-1 misinformation spreads fast, posting a semaglutide-hashtagged video with no false claims is, by the floor-level standards of health TikTok, not harmful.

What is worth flagging is the hashtag strategy itself. Tagging content with "semaglutideforweightloss" when the video has no informational value about that topic is a form of audience misdirection. People searching for real information about GLP-1 medications, a class of drugs with real side effect profiles including nausea, pancreatitis risk, and potential thyroid concerns noted in prescribing information, get served entertainment instead. That is not a safety issue here, but it is a signal of how unreliable hashtag-based health content discovery is on short-form video platforms.

What should you actually know?

If you landed on this video looking for information about semaglutide, here is what the research actually supports. Semaglutide works by mimicking GLP-1, a gut hormone that slows gastric emptying, reduces appetite, and signals satiety to the brain. It does not cure obesity or type 2 diabetes. It manages symptoms and metabolic markers while you take it.

Discontinuation data is important and underreported on TikTok. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained most of their lost weight within a year of stopping semaglutide, which means this is a long-term or indefinite treatment for many people, not a short course. Side effects including nausea, vomiting, and gastroparesis-like symptoms are real and documented. Anyone considering GLP-1 therapy should be doing that with a licensed prescriber who has reviewed their full medical history, not based on hashtag content.

• Semaglutide is FDA-approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management).
• Compounded semaglutide is not equivalent to FDA-approved branded formulations, regardless of what any TikTok post implies.
• Weight regain after stopping is well-documented in peer-reviewed literature.
• GLP-1 medications carry a boxed warning for thyroid C-cell tumor risk in rodent studies; clinical significance in humans remains under study.